https://www.selleckchem.com/pr....oducts/semaxanib-su5
It was an amazing phenomenon that CDAI and PDAI scores occurred an obviously transient rise with the use of stem cells after 1 month (both of P 0.05), while they returned to the baseline level by giving stem cells 3 months later. Furthermore, the incidence rate of treatment-related adverse events in the stem cell group was significantly lower than in the placebo group (RR 0.58, 95% CI 0.30 to 1.14). Our study has highlighted that stem cells was a promising method in the treatment of Crohn's fistula based on its higher effi
Beğen
Yorum Yap
Paylaş
